Diren Beyoğlu, Ph.D., CBiol, MRSB
Associate Director and Associate Professor, Arthur G. Zupko’s Systems Pharmacology and Pharmacogenomics Diren.Beyoglu@liu.edu
PhD, Marmara University, Faculty of Pharmacy, Turkey in Pharmaceutical Toxicology
MSc, Marmara University, Faculty of Pharmacy, Turkey in Pharmaceutical Toxicology
BSc, Marmara University, Faculty of Pharmacy, Turkey in Pharmacy
Dr. Diren Beyoğlu received a BSc in Pharmacy from Marmara University in 2000. She received an MSc in Pharmaceutical Toxicology in 2002 and a PhD in Pharmaceutical Toxicology in 2006, both from Marmara University in Turkey. She has held the positions of Research Assistant, Lecturer, and Assistant Professor in Pharmaceutical Toxicology at Marmara University. Her research in Turkey concerned determination of chemical contaminants in foodstuffs. She trained in Molecular Pharmacogenetics with Professor Ondřej Slanař, Director, Institute of Pharmacology, Charles University in Prague and in mass spectrometry-based metabolomics in the laboratory of Dr. Frank J. Gonzalez, National Cancer Institute, NIH. In 2011, she was appointed as Research Fellow, Hepatology Research Group, University of Bern, Switzerland and promoted to Senior Research Fellow and Group Leader in 2013. She assisted in Bern to develop a clinical metabolomics program, which ultimately led to the creation of the Clinical Metabolomics Center (now a Waters Center of Innovation) in the Inselspital Teaching Hospital, Bern. In 2018, she joined LIU as Associate Director and Associate Professor, Arthur G. Zupko’s Systems Pharmacology and Pharmacogenomics. Her research has primarily focused on clinical applications of metabolomics and lipidomics in the areas of hepatology and oncology. She published the conceptualizing of the glycine deportation system, where it was hypothesized that glycine conjugation of aromatic acids, such as benzoic acid, was not in fact a means of eliminating these acids from the body, but rather these acids were used as a means of regulating glycine homeostasis, through its removal by conjugation and ultimate urinary excretion; the first report of integrated metabolomics and transcriptomics in hepatocellular carcinoma (HCC); first report of the effect on lipid signaling molecules of the inactivation of a tumor suppressor gene in that tissue (Hint1 in the liver); first report of the induction of the polyol pathway in patients infected with Hepatitis C virus, with implications for progression to HCC; first report of the detailed lipidomic landscape of acute myeloid leukemia, a disease known to display perturbations in lipid metabolism; first report of the induction of the Warburg effect in gamma irradiated cells in vitro; first report of the use of robust regression analysis in bioinformatics applied to metabolomics.
My research career began in pharmaceutical toxicology at Marmara University but then translated to clinical metabolomics and lipidomics at the University of Bern, Switzerland. Since arriving at LIU, I have begun to focus on how the new laboratory, that will combine high-end mass spectrometry and nucleic acid analyses, can best enhance the research profile of the College of Pharmacy and the clinical environment in Brooklyn and beyond.
Beyoğlu D, Zhou Y, Chen C, Idle JR. Mass isotopomer-guided decluttering of metabolomic data to visualize endogenous biomarkers of drug toxicity. Biochem Pharmacol 2018; 156: 491-500
Simillion C, Semmo N, Idle JR, Beyoğlu D. Robust regression analysis of GCMS data reveals differential rewiring of metabolic networks in hepatitis B and C patients. Metabolites 2017; 7: pii: E51. doi: 10.3390/metabo7040051.
Keogh A, Şenkardeş S, Idle JR, Küçükgüzel ŞG, Beyoğlu D. A novel anti-hepatitis C virus and antiproliferative agent alters metabolic networks in HepG2 and Hep3B cells. Metabolites 2017; 7: doi:10.3390/metabo7020023.
Patel DP, Krausz KW, Xie X, Beyoğlu D, Gonzalez FJ, Idle JR. Metabolic profiling of energy metabolism in high-fat diet-fed obese mice. PLoS ONE 2017; 12: e0177953. doi: 10.1371/journal.pone.0177953. eCollection 2017.
Golla S, Golla JP, Krausz KW, Mann SK, Simillion C, Beyoğlu D, Idle JR, Gonzalez FJ. Metabolomic analysis of mice exposed to γ-irradiation reveals a systemic understanding of total body radiation exposure. Radiat Res 2017; 187: 612-629.
Pabst T, Kortz L, Fiedler GM, Ceglarek U, Idle JR, Beyoğlu D. The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin 2017; 7: 105-114.
Wang M, Keogh A, Treves S, Idle JR, Beyoğlu D. The metabolomic profile of gamma-irradiated human hepatoma and muscle cells reveals metabolic changes consistent with the Warburg effect. Peer J 2016; 4: e1624. doi: 10.7717/peerj.1624. eCollection 2016.
Semmo N, Weber T, Idle JR, Beyoğlu D. Metabolomics reveals that aldose reductase activity due to AKR1B10 is upregulated in hepatitis C infection. J Viral Hepat 2015; 22: 617-624.
Beyoğlu D, Krausz KW, Martin J, Maurhofer O, Dorow J, Ceglarek U, Gonzalez FJ, Dufour JF, Idle JR. Disruption of tumor suppressor gene Hint1 leads to remodeling of the lipid metabolic phenotype of mouse liver. J Lipid Res 2014; 55: 2309-2319.
Beyoğlu D, Idle JR. Painting the liver with lasers: The future of the liver histology? Hepatology 2014; 59: 757-760.
Beyoğlu D, Idle JR. A history and overview of phenotypic variability in CYP2D6 activity. In: CYP2D6: genetics, pharmacology and clinical relevance. Baumann P. (Ed.), Future Medicine, London, UK (2014).
Beyoğlu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol 2013; 59: 842-858.
Cheng J, Zhen Y, Miksys S, Beyoğlu D, Krausz KW, Tyndale RF, YuA, Idle JR, Gonzalez FJ. Potential role of CYP2D6 in the central nervous system. Xenobiotica 2013; 43: 973-984.
Beyoğlu D, Imbeaud S, Maurhofer O, Bioulac-Sage P, Zucman-Rossi J, Dufour JF, Idle JR. Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology 2013; 58: 229-238.
Beyoğlu D, Idle JR. Metabolomics and its potential in drug development. Biochem Pharmacol 2013; 85: 12-20.
*Fahrner R, *Beyoğlu D, Beldi G, Idle JR. Metabolomic markers for intestinal ischemia in a mouse model. J Surg Res 2012; 178: 879-887 (*co-first authors).
Beyoğlu D, Idle JR. The glycine deportation system and its pharmacological consequences. Pharmacol Ther 2012; 135: 151-67.
Beyoğlu D, Smith RL, Idle JR. Dog bites man or man bites dog? The enigma of the amino acid conjugations. Biochem Pharmacol 2012; 83: 1331-1339.
Şardaş S, Omurtag GZ, Monteiro IFC, Beyoğlu D, et al. Assessment of DNA Damage and Protective Role of Vitamin E Supplements after Exhaustive Exercise by Comet Assay in Athletes. J Clinic Toxicol 2012; S5: 001. doi:10.4172/2161-0495.S5-001.
Patterson AD, Maurhofer O, Beyoğlu D, Lanz C, Krausz KW, Pabst T, Gonzalez FJ, Dufour JF, Idle JR. Aberrant lipid metabolism in hepatocellular carcinoma revealed by plasma metabolomics and lipid profiling. Cancer Res 2011; 71: 6590-6600.
Şardaş S, Omurtag GZ, Tozan A, Gül H, Beyoğlu D. Evaluation of DNA damage in construction site workers occupationally exposed to welding fumes and solvent based paints in Turkey. Toxicol Ind Hlth 2010; 26: 601-608.
Beyoğlu D, Ozkozacı T, Akici N, Omurtag G, Akici A, Ceran O, Şardaş S. Assessment of DNA damage in children exposed to indoor tobacco smoke. Int J Hyg Environ Hlth 2010; 213: 40-43.
Beyoğlu D, Omurtag GZ. Occurrence of naphthalene in honey in Turkey by HPLC. J Food Prot 2007; 70: 1735-1738.
Omurtag GZ, Beyoğlu D. Occurrence of deoxynivalenol (vomitoxin) in beer in Turkey detected by HPLC. Food Control 2007; 18: 163-166.
Omurtag GZ, Yazıcıoğlu D, Beyoğlu D, Tozan A, Atak G. A review on fumonisin and trichothecene mycotoxins in foods consumed in Turkey. Bull Tech Univ Istanbul 2006; 54: 39-44.
Omurtag GZ, Beyoğlu D. Occurrence of deoxynivalenol (vomitoxin) in processed cereals and pulses in Turkey. Food Addit Contam 2003; 20: 405-409.
Join the LIU Community!
We can't wait to welcome you to Shark Nation.
The application process is quick and easy, but if you have
any questions, our admissions counselors are here to help.